IL191311A - Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury - Google Patents

Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury

Info

Publication number
IL191311A
IL191311A IL191311A IL19131108A IL191311A IL 191311 A IL191311 A IL 191311A IL 191311 A IL191311 A IL 191311A IL 19131108 A IL19131108 A IL 19131108A IL 191311 A IL191311 A IL 191311A
Authority
IL
Israel
Prior art keywords
disease
parkinson
medicaments
alzheimer
progression
Prior art date
Application number
IL191311A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37716856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL191311(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Lohmann Therapie Syst Lts filed Critical Novartis Ag
Publication of IL191311A publication Critical patent/IL191311A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL191311A 2005-12-01 2008-05-07 Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury IL191311A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74151105P 2005-12-01 2005-12-01
PCT/US2006/039557 WO2007064407A1 (en) 2005-12-01 2006-10-10 Transdermal therapeutic system

Publications (1)

Publication Number Publication Date
IL191311A true IL191311A (en) 2015-02-26

Family

ID=37716856

Family Applications (4)

Application Number Title Priority Date Filing Date
IL191311A IL191311A (en) 2005-12-01 2008-05-07 Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury
IL234291A IL234291A (en) 2005-12-01 2014-08-25 Ribstigmine for use in the prevention, treatment or delay of the progression of dementia or Alzheimer's disease
IL234364A IL234364A (en) 2005-12-01 2014-08-28 Rivastigmine to prevent or delay the progression of XIV or Alzheimer's disease and a therapeutic transdermal system containing it
IL250734A IL250734A0 (en) 2005-12-01 2017-02-23 Transdermal therapeutic system

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL234291A IL234291A (en) 2005-12-01 2014-08-25 Ribstigmine for use in the prevention, treatment or delay of the progression of dementia or Alzheimer's disease
IL234364A IL234364A (en) 2005-12-01 2014-08-28 Rivastigmine to prevent or delay the progression of XIV or Alzheimer's disease and a therapeutic transdermal system containing it
IL250734A IL250734A0 (en) 2005-12-01 2017-02-23 Transdermal therapeutic system

Country Status (31)

Country Link
US (3) US20070128263A1 (https=)
EP (5) EP3235495A1 (https=)
JP (3) JP2009517468A (https=)
KR (7) KR20180050441A (https=)
CN (2) CN102048713A (https=)
AR (2) AR057152A1 (https=)
AT (1) AT11185U1 (https=)
AU (1) AU2006320919B2 (https=)
BR (2) BRPI0619758A2 (https=)
CA (1) CA2563110A1 (https=)
DE (2) DE14163637T1 (https=)
DK (5) DK2292219T3 (https=)
EC (1) ECSP088469A (https=)
ES (1) ES2414455T3 (https=)
FI (1) FI10268U1 (https=)
GT (1) GT200800075A (https=)
IL (4) IL191311A (https=)
MA (1) MA30022B1 (https=)
MY (2) MY151020A (https=)
NO (1) NO20082753L (https=)
NZ (1) NZ568273A (https=)
PH (2) PH12013500772B1 (https=)
PL (1) PL2292219T4 (https=)
PT (1) PT2292219E (https=)
RU (1) RU2450805C2 (https=)
SG (1) SG2014014989A (https=)
SI (1) SI2292219T1 (https=)
TN (1) TNSN08238A1 (https=)
TW (1) TWI389709B (https=)
WO (1) WO2007064407A1 (https=)
ZA (1) ZA200803882B (https=)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
GB0823554D0 (en) 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
US20100267302A1 (en) * 2009-04-17 2010-10-21 3M Innovative Properties Company Silicone gel adhesive construction
US20100286260A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Ltd. Milnacipran formulations
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
DK2493457T3 (en) 2009-10-30 2017-10-02 Ix Biopharma Ltd QUICK-SOLVING SOLID DOSAGE FORM
WO2011073362A1 (en) 2009-12-18 2011-06-23 Novartis Ag Process for the preparation of optically active compounds using pressure hydrogenation
BR112012017168B1 (pt) * 2009-12-22 2022-03-15 Luye Pharma Ag Sistemas terapêuticos transdérmicos, seu processo de preparação, e usos de um polímero ou copolímero
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
RU2578971C2 (ru) * 2010-06-17 2016-03-27 Лтс Ломанн Терапи-Системе Аг Трансдермальное введение мемантина
DE102010026903A1 (de) 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
MX346041B (es) 2010-07-21 2017-03-03 3M Innovative Properties Company * Composiciones adhesivas transdermicas, dispositivos y metodos.
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120046383A1 (en) * 2010-08-19 2012-02-23 Terumo Kabushiki Kaisha Silicone rubber composition
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
RS54173B1 (sr) * 2010-12-14 2015-12-31 Acino Ag Transdermalni terapijski sistem za davanje aktivne supstance
KR101788802B1 (ko) * 2010-12-24 2017-10-20 주식회사 삼양바이오팜 리바스티그민을 함유하는 경피흡수제제
KR101054317B1 (ko) * 2011-01-28 2011-08-08 신신제약 주식회사 리바스티그민을 함유하는 경피흡수제제
KR101317158B1 (ko) * 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012161489A2 (ko) * 2011-05-20 2012-11-29 에스케이케미칼 주식회사 리바스티그민 함유 패취
KR20120130073A (ko) * 2011-05-20 2012-11-28 에스케이케미칼주식회사 리바스티그민 함유 패취
WO2013031992A1 (ja) 2011-08-31 2013-03-07 積水メディカル株式会社 貼付剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
KR101399035B1 (ko) * 2011-12-22 2014-05-28 주식회사 트랜스덤 리바스티그민을 함유하는 경피흡수제제
DE102012000369A1 (de) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
US8871245B2 (en) 2012-02-28 2014-10-28 Nichiban Co., Ltd. Transdermal patch
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US20150051559A1 (en) * 2012-04-05 2015-02-19 Sparsha Pharma International Private Limited Transdermal patch for treatment of dementia or alzheimer type dementia
US10758494B2 (en) 2012-06-12 2020-09-01 KM Transderm Ltd. Rivastigmine-containing adhesive patch
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104582693A (zh) * 2012-08-15 2015-04-29 道康宁公司 多层药物递送系统
EP2893927A4 (en) * 2012-09-03 2016-03-09 Nipro Patch Co Ltd SKIN PATCH
KR20140038237A (ko) * 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
US20140083878A1 (en) * 2012-09-21 2014-03-27 Mylan Inc. Transdermal drug delivery device
US9895320B2 (en) 2012-09-28 2018-02-20 KM Transderm Ltd. Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
RU2560668C2 (ru) * 2013-03-04 2015-08-20 Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии" Трансдермальный седативный фармацевтический гель для лечения психоэмоциальных расстройств
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AR095259A1 (es) * 2013-03-15 2015-09-30 Noven Pharma Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
WO2014152454A1 (en) * 2013-03-15 2014-09-25 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing rivastigmine
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
TWI745577B (zh) * 2013-06-12 2021-11-11 日商Ｋｍ特蘭斯達股份有限公司 經皮吸收製劑
JP6427733B2 (ja) 2013-06-12 2018-11-28 株式会社 ケイ・エム トランスダーム 皮膚貼付用粘着シートおよびそれを用いた経皮吸収製剤
JP6726096B2 (ja) 2013-07-03 2020-07-22 エルテーエス ローマン テラピー−システメ アーゲー 電子部品を有する経皮治療システム
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
EP3081211A4 (en) 2013-12-12 2017-10-11 Hisamitsu Pharmaceutical Co., Inc. Patch with cover member and patch kit with cover member
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
EP3129012A4 (en) 2014-04-08 2017-10-11 Teikoku Pharma USA, Inc. Rivastigmine transdermal compositions and methods of using the same
WO2015174502A1 (ja) 2014-05-15 2015-11-19 ニチバン株式会社 リバスチグミンを含有する貼付剤のための包装体
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
CN106456566B (zh) 2014-05-20 2020-06-16 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
CN204119542U (zh) 2014-09-24 2015-01-21 上海荣威塑胶工业有限公司 一种ptc加热器
CN104523656A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 一种卡巴拉汀缓释透皮贴剂及其制备方法
EP3228309B1 (en) 2014-12-05 2024-11-06 KM Transderm Ltd. Adhesive sheet for attachment to skin and percutaneous absorption preparation using same
DE102015107743A1 (de) 2015-05-18 2016-11-24 Bsn Medical Gmbh Silikongelbeschichtete adhäsive Schichtstruktur
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
CN109640976B (zh) 2016-08-22 2023-10-17 救急药品工业株式会社 贴附剂
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
CN115813888A (zh) * 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
KR102033686B1 (ko) * 2017-05-19 2019-10-18 보령제약 주식회사 도네페질을 함유하는 마이크로니들 경피 패치
CN111093639A (zh) 2017-09-05 2020-05-01 罗曼治疗系统股份公司 用于卡巴拉汀经皮给药的经皮治疗系统
US20210038532A1 (en) * 2018-03-13 2021-02-11 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
US20210000756A1 (en) * 2018-03-13 2021-01-07 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
CN111971033A (zh) * 2018-03-13 2020-11-20 罗曼治疗系统股份公司 包含有机硅丙烯酸杂化聚合物的透皮治疗系统
EP3810101A1 (en) 2018-06-19 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing rivastigmine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
TWI781370B (zh) 2019-01-31 2022-10-21 日商久光製藥股份有限公司 貼附劑
EP3996692B1 (en) * 2019-07-09 2025-06-11 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system comprising an active agent-containing layer comprising a silicone-containing polymer and a skin contact layer comprising a silicone gel adhesive
BR112021023509A2 (pt) * 2019-07-09 2022-01-18 Lts Lohmann Therapie Systeme Ag Sistema terapêutico transdérmico compreendendo uma camada contendo o agente ativo compreendendo um polímero acrílico e uma camada de contato com a pele compreendendo um adesivo de gel de silicone
CN113616625B (zh) * 2021-08-26 2023-05-30 大连科翔科技开发有限公司 一种卡巴拉汀的长效透皮贴剂
CN120583943A (zh) * 2023-02-01 2025-09-02 Lts罗曼治疗系统股份公司 用于透皮施用石杉碱甲的透皮治疗系统

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US6316023B1 (en) 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
AU2002235155A1 (en) * 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
DE10103860B4 (de) 2001-01-30 2004-12-23 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung
CA2459146A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
DE10159745A1 (de) * 2001-12-05 2003-07-03 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit verbessertem Langzeittragekomfort
PT1509232E (pt) * 2002-05-31 2009-01-07 Lundbeck & Co As H Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
TW200418446A (en) * 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20070166363A1 (en) 2004-02-19 2007-07-19 Lane Roger M Use of cholinesterase inhibitors for treating vascular depression
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
EP2596889B1 (en) * 2011-11-23 2017-04-26 Sandvik Intellectual Property AB A cutting insert and a milling tool

Also Published As

Publication number Publication date
GT200800075A (es) 2010-06-01
KR20210008440A (ko) 2021-01-21
ES2414455T3 (es) 2013-07-19
KR20220156666A (ko) 2022-11-25
PL2292219T3 (pl) 2013-09-30
NO20082753L (no) 2008-08-19
JP2013177419A (ja) 2013-09-09
EP2786748A1 (en) 2014-10-08
HK1153646A1 (en) 2012-04-05
IL234291A (en) 2017-02-28
NZ568273A (en) 2011-06-30
DK201300059U3 (da) 2013-05-13
ZA200803882B (en) 2009-03-25
AU2006320919B2 (en) 2011-04-28
BRPI0619758A2 (pt) 2011-10-18
TW200732001A (en) 2007-09-01
KR20130143729A (ko) 2013-12-31
BR122013013162A2 (pt) 2015-06-30
IL234364A (en) 2016-06-30
DE202006021172U1 (de) 2013-05-07
CN102048713A (zh) 2011-05-11
EP2292219A1 (en) 2011-03-09
AT11185U1 (de) 2010-06-15
MY151020A (en) 2014-03-31
KR20170033449A (ko) 2017-03-24
TNSN08238A1 (en) 2009-10-30
DK201300015Y4 (da) 2016-02-12
SI2292219T1 (sl) 2013-08-30
EP2286802A1 (en) 2011-02-23
PL2292219T4 (pl) 2014-03-31
KR20180050441A (ko) 2018-05-14
ECSP088469A (es) 2008-07-30
WO2007064407A1 (en) 2007-06-07
KR20080071581A (ko) 2008-08-04
CA2563110A1 (en) 2007-06-01
US20140134230A1 (en) 2014-05-15
EP2292219B9 (en) 2015-02-18
AR097045A2 (es) 2016-02-17
MY162986A (en) 2017-07-31
PT2292219E (pt) 2013-06-24
FI10268U1 (fi) 2013-10-18
DK201300015U1 (en) 2013-02-08
TWI389709B (zh) 2013-03-21
US20130266633A1 (en) 2013-10-10
JP6298034B2 (ja) 2018-03-20
JP2009517468A (ja) 2009-04-30
DK201300059U1 (da) 2013-04-29
DK201600113Y4 (da) 2017-06-09
JP5938612B2 (ja) 2016-06-22
AU2006320919A1 (en) 2007-06-07
DK2292219T3 (da) 2013-06-24
DK201600113U1 (da) 2017-01-13
IL250734A0 (en) 2017-04-30
RU2008126459A (ru) 2010-01-20
DK201300014U1 (da) 2013-02-08
DK201300014U3 (da) 2013-05-13
DE14163637T1 (de) 2015-06-03
US20070128263A1 (en) 2007-06-07
PH12013500771A1 (en) 2016-01-18
EP3235495A1 (en) 2017-10-25
EP1959937A1 (en) 2008-08-27
JP2016104737A (ja) 2016-06-09
MA30022B1 (fr) 2008-12-01
PH12013500772B1 (en) 2018-04-20
PH12013500772A1 (en) 2016-01-18
RU2450805C2 (ru) 2012-05-20
EP2292219B1 (en) 2013-06-12
KR20140072108A (ko) 2014-06-12
AR057152A1 (es) 2007-11-21
SG2014014989A (en) 2014-06-27
CN101312717A (zh) 2008-11-26

Similar Documents

Publication Publication Date Title
IL191311A (en) Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury
ZA200802897B (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease
IL190295A0 (en) Combination therapy comprising substituted oxazolidinones for the prevention and treatment of cerebral circulatory disorders
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
IL163102A (en) Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders
IL202158A (en) History of Oxadiazole, Pharmaceuticals Containing Them and Their Use in the manufacture of Drugs for the Treatment of Neurological and Psychiatric Disorders
EP1979324A4 (en) IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF COGNITIVE DISORDER, MORBUS ALZHEIMER, NEURODEGENERATION AND DEMENTIA.
WO2008103472A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
GB0412753D0 (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
ZA200806114B (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL184371A (en) Use of an anti il-31ra antibody in the manufacture of a medicament for treating skin disorders
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
PL2104682T3 (pl) Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
EP2035412A4 (en) MUSCARINIC RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
IL195431A0 (en) Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
IL195441A0 (en) Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
ZA200607531B (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
IL178427A0 (en) 1,2-diarylimidazole-4-carboxamide compounds, processes for their preparation and use thereof in the treatment of obesity, psychiatric and neurological disorders
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed